Navigation Links
Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
Date:7/26/2011

PHILADELPHIA, July 26, 2011 /PRNewswire-USNewswire/ -- The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania announces the launching of a first-of-its-kind interdisciplinary center focused on discovering novel treatments for orphan diseases. The Center will bring together, without institutional walls, all necessary approaches to attacking and treating orphan diseases: establishing dedicated research support facilities, translating findings into therapies, fostering targeted grant awards, and educating physicians and researchers.  

Formation of the new Penn Center for Orphan Disease Research and Therapy was catalyzed by a $10 million gift from an anonymous donor, whose vision matched that of Penn Medicine in developing treatments for these diseases.  The Center will fill a crucial need by providing the core laboratories, techniques, collaborative relationships, and expertise to lead an international, coordinated effort in the eradication of orphan diseases. Key among these resources is a state-of-the-art, robotically controlled drug screening laboratory that enables researchers from around the world to rapidly probe existing compound libraries for effective, orphan disease treatments.

Diseases are classified as orphan when they affect fewer than 200,000 people. However, as there are approximately 7,000 diseases now identified in this population, more than 25 million Americans are currently afflicted. Many of these diseases are caused by genetic mutations and are diagnosed in children. Research in many orphan diseases has lagged behind other major disease categories, such as diabetes and cardiovascular disease, in part because of a relative lack of technical expertise and funding mechanisms. Penn's Center will specifically address these needs.

"The research and development marketplace is not designed to optimally support research to develop the therapies so desperately needed for orphan diseases," explains Glen N. Gaulton, Ph.D., Executive Vice Dean and Chief Scientific Officer at the Perelman School. "Penn's new Center for Orphan Disease Research and Therapy will build not only strong collaborative relationships throughout Penn, but also with other leading academic medical centers, as well as public and private institutions -- all designed to translate innovative research into the clinic. There's simply nothing else like it."

"This is a wonderful example of philanthropy in action," says J. Larry Jameson, M.D., Executive Vice President for the Health System and Dean of the Perelman School of Medicine. "The Center will be a natural extension of Penn's expertise in orphan diseases, and this strategic investment will galvanize support for orphan disease research around the globe. I am proud that Penn Medicine is taking a clear leadership position in transforming the health of millions."

Jameson adds that he is delighted that his predecessor, former Perelman School Dean Arthur H. Rubenstein, MBBCh, has agreed to serve as Acting Director for the Center, while an international search is conducted for a permanent director.

http://www.med.upenn.edu/

CONTACT: Karen Kreeger
(215) 349 -5658
Karen.kreeger@uphs.upenn.edu


'/>"/>
SOURCE The Perelman School of Medicine at the University of Pennsylvania
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark
2. Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
3. Metabolic Solutions Development Company Receives $773,000 From the Alzheimers Drug Discovery Foundation to Fund Phase 2a Trial
4. Unity Management Group, MCC Receives Authorization for Second Purchase Order From Bristol Meyers Squibb
5. TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards
6. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
7. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
8. China-Biotics, Inc. Receives NASDAQ Delisting Notification
9. UCSB professor receives Presidential Green Chemistry Challenge Award
10. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
11. Huda Y. Zoghbi, MD, Receives $500,000 Gruber Neuroscience Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... today announced several positive developments that position the Company for the future. ... the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, Curtis ...
(Date:5/25/2016)... ... 2016 , ... Thailand’s Board of Investment’s New York office, ... Located at booth number 7301, representatives from the Thai Government, research organizations, and ... biotechnology and life sciences sector. , Deputy Secretary General of the Thailand ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... for information (RFI) issued by the Office of the National Coordinator for Health ... experience, and determines if clinically relevant data were available when and where it ...
Breaking Biology Technology:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
Breaking Biology News(10 mins):